Proneural basic helix-loop-helix transcription factors such as Neurogenin are activators of neuronal gene expression. Recent studies show they reinforce neuronal differentiation by also inhibiting the expression of glial genes, and are required in vivo to prevent premature and excessive gliogenesis.
Do you ever wonder how it is possible to make a commitment? For example, how do neural stem cells commit to a neuronal fate, steadfastly avoiding the temptations of gliogenesis? Our answer has been that stem cells express master regulators of neuronal differentiation, the proneural basic helix-loop-helix (bHLH) transcription factors, which promote the expression of a cascade of other genes that create neuronal identity [1] . The proneural bHLH genes are necessary for the formation of many different types of neuron in the central and peripheral nervous systems. But is it enough for proneural genes to induce the expression of neuronal genes, or must they also employ other mechanisms to keep stem cells from seductive second thoughts of gliogenesis? Recent studies [2] [3] [4] indicate that, in addition to promoting neuronal differentiation, proneural bHLH transcription factors also act through independent mechanisms to inhibit gliogenesis.
Proneural bHLH proteins regulate the onset and extent of gliogenesis in vivo. Tomita and colleagues [2] studied mice that were deficient for the proneural genes Mash1 and Math3 and observed increased gliogenesis in the tectum, hindbrain and retina, in addition to reduced neurogenesis. Nieto and colleagues [3] studied mice that were deficient for the proneural genes Mash1 and Neurogenin2 and observed evidence of increased cortical gliogenesis in addition to reduced neurogenesis. And now Sun and colleagues [4] have provided a mechanism by which proneural bHLH factors may regulate gliogenesis: Neurogenin1 inhibits gliogenesis by binding the CBP/Smad1 or p300/Smad1 transcriptional co-activator and sequestering it away from the promoters of glial genes, preventing transcription.
These studies have two important implications for understanding how lineage determination occurs in stem cells. Transcription factors that are important regulators of lineage determination in the hematopoietic system consistently inhibit alternative cell fates in addition to promoting lineage-specific differentiation [5] . The demonstration that proneural bHLH proteins inhibit gliogenesis suggests that it may be a general strategy for lineage-determining transcription factors to inhibit alternative cell fates while acting as transcriptional activators to promote lineage-specific differentiation. These observations may also provide insight into the mechanism behind the recent discovery that Notch activation can promote glial lineage determination by neural stem cells [6] [7] [8] [9] . As Notch inhibits the expression of proneural bHLH genes, including Mash1 [6] and Neurogenin [10] , these recent papers suggest that Notch may promote gliogenesis in stem cells by relieving the inhibition imposed by proneural bHLH genes.
What happens to cortical progenitors in the absence of proneural bHLH transcription factors? Nieto et al. [3] analyzed mice that were deficient for Mash1 and/or Neurogenin2 and concluded that, in addition to reduced neurogenesis, glial precursors are generated earlier and in greater numbers in the double mutant mice. However, only a minority of animals showed premature glial fibrillary acidic protein (GFAP) expression, suggesting that loss of Mash1 and Neurogenin2 may accelerate glial lineage determination but that other factors determine the timing of overt differentiation. Tomita et al. [2] observed accelerated gliogenesis in the tectum and hindbrain, using both early and late glial markers, but not in the retinas of Mash1/Math3-deficient mice. Thus gliogenesis is accelerated to different extents in different regions of the nervous system, depending on which proneural genes are deleted.
In vitro clonal analysis of cortical progenitors from Neurogenin2 and/or Mash1 deficient mice suggests that Mash1 deficiency has a greater effect than Neurogenin2 deficiency on glial lineage determination. Nieto et al. [3] examined the relative frequencies of progenitors that formed neuron-only, glial-only, or mixed -multipotentcolonies. Neurogenin2-deficient progenitors do not differ in the types of colony they form relative to wild-type cells, suggesting that Mash-1 compensates for the lack of Neurogenin2 in these mice. In Mash-1 deficient mice, the Neurogenin2-expressing subset of progenitors also form colonies similar to wild-type cells, but the subset of cells that do not express Neurogenin2 exhibit a dramatic increase in clones that make only glia. This suggests that Mash-1 and Neurogenin2 can largely compensate for each other, but that in the absence of both proneural genes, at least one subset of cortical progenitors exhibits increased gliogenesis.
So what happens in double mutant mice? Mice deficient for both Mash-1 and Neurogenin2 exhibit an increase in mixed clones and a decrease in neuronal clones but no change in clones containing only glia [3] . Given the appearance of an increase in the number of immature glia in double mutants in vivo, and the increased gliogenesis in one subset of progenitors from the Mash-1-deficient mice, this failure to observe increased glial commitment in the double mutant is puzzling. One possible explanation is that proneural genes are necessary to avoid premature glial lineage determination, but loss of proneural genes is not sufficient to cause glial commitment. Perhaps the progenitors from double mutant mice are specified to undergo gliogenesis but have not yet committed to the glial lineage, so they form mixed colonies in culture but behave like immature glia in vivo. Consistent with this hypothesis is the observation that, unlike wild-type mixed clones, the mixed clones from double mutant mice contain mainly glia and very few neurons [3] . More data will be required to understand the significance of these observations. A complementary paper by Sun et al. [4] describes mechanisms by which Neurogenin1 may inhibit glial lineage determination by multipotent progenitors. Sun et al. observed that Neurogenin1 strongly inhibits leukemia inhibitory factor (LIF)-induced glial differentiation by cortical progenitors in culture, even in cells that fail to undergo overt neuronal differentiation. This suggests that Neurogenin1 may inhibit gliogenesis independently of its ability to promote neuronal differentiation. Within the GFAP promoter, the STAT -'signal transducer and activator of transcription' -transcription factor binding site is necessary for the full Neurogenin1-mediated inhibition of GFAP expression; Neurogenin1 binding sites are not necessary. This suggests that inhibition does not require DNA binding by Neurogenin1.
The STAT binding site promotes GFAP transcription by binding a complex of STAT1/3, activated by LIF/ciliary neurotrophic factor (CNTF) signaling, the ubiquitously expressed transcriptional coactivators CBP or p300, and Smad1, activated by bone morphogenetic protein (BMP) signaling. Sun et al. [4] found that Neurogenin1 inhibits the assembly of this complex by binding to both CBP and Smad1, interfering with the ability of CBP/Smad1 to bind STAT3 (see Figure 1 ). On top of this effect, Neurogenin1 also blocks LIF signaling by preventing STAT activation. Thus, Neurogenin1 may inhibit glial lineage determination by sequestering the CBP/p300/Smad1 transcriptional complex away from the promoters of glial genes, as well as by suppressing STAT-mediated signal transduction.
In addition to implicating Neurogenin1 as an inhibitor of gliogenesis, the work reported by Sun et al. [4] may also explain why BMPs promote neurogenesis by stem cells in some cases, while promoting gliogenesis in other cases. In progenitors that express high levels of Neurogenin1, BMP promotes neurogenesis, whereas in progenitors that express low levels of Neurogenin1, BMP promotes gliogenesis. This suggests that, in the presence of Neurogenin1, all the endogenous CBP/p300/Smad1 is bound by Neurogenin and diverted to neuronal promoters, preventing it from interacting with STATs at glial promoters. In the absence of Neurogenin1, CBP/p300/Smad1 is free to interact with STATs to activate glial promoters.
Of course these interpretations require endogenous CBP/p300 levels to be limiting. While Sun et al. [4] present considerable evidence to support this model, it has not yet been demonstrated that endogenous CBP/p300 levels are limiting or that endogenous Neurogenin can bind to all available CBP/p300. Nonetheless, the available data suggest that Neurogenin1 is a molecular switch in stem Neurogenin1 inhibits gliogenesis (red arrow pathway) by binding and sequestering the CBP/p300/Smad1 transcriptional co-activator. In the absence of Neurogenin1, the CBP/p300/Smad1 complex is recruited to the promoters of glial genes by binding to activated STAT1/3. This results in the expression of genes such as GFAP and glial differentiation. When present, Neurogenin1 binds the CBP/p300/Smad1 complex, recruiting it to the promoters of neuronal genes (green arrow pathway), and sequestering it from the promoters of glial genes. Neurogenin1 also inhibits the activation of STAT1/3. By these two mechanisms, Neurogenin1 not only promotes the expression of neuronal genes but inhibits the expression of glial genes. Consistent with this model, bone morphogenetic proteins (blue arrow) promote neurogenesis in the presence of Neurogenin1 and gliogenesis in the absence of Neurogenin1. Notch activation may promote glial lineage determination by inhibiting the expression of proneural bHLH genes, such as Neurogenin, and perhaps through other proneural geneindependent mechanisms. This figure was adapted from Sun et al. [4] . LIF-R, leukemia inhibitory factor receptor; BMP-R, bone morphogenetic protein receptor; NeuroD, a neurogenic bHLH transcription factor, downstream of Neurogenin1. The inhibition of gliogenesis by proneural bHLH genes has implications for understanding how Notch activation promotes gliogenesis in stem cells [6, 9] . As Notch inhibits the expression of proneural bHLH genes, Notch activation may inhibit neurogenesis and relieve the inhibition of gliogenesis. But is this the whole story? Even transient Notch activation accelerates glial lineage determination in both neural crest stem cells [6] and central nervous system stem cells [9] . Could simply inhibiting neurogenesis and relieving the inhibition of gliogenesis account for irreversible and accelerated gliogenesis? Or must Notch promote gliogenesis in additional ways that are independent of its inhibition of proneural bHLH genes?
By analogy to other lineage determination factors, Notch pathway genes might directly activate the transcription of glial genes in addition to inhibiting alternative fates. Tanigaki et al. [9] found that constitutively active Notch is capable of slightly promoting GFAP expression in the absence of CNTF, and that this promotion does not require STAT3 activation or even the STAT binding site in the GFAP promoter. This suggests that the promotion of gliogenesis by Notch does not depend on signaling through the STAT pathway and is not entirely based on inhibiting the sequestration by Neurogenin of CBP/p300/Smad1 from the STAT binding site [4] . Thus Notch may promote gliogenesis in additional ways beyond the inhibition of proneural gene expression. As all things Notch related turn out to be unendingly complicated this should not be surprising.
It seems that commitment is engendered by the impetus to traverse one path, and the inability to access other paths. Proneural genes drive neuronal differentiation of stem cells while inhibiting glial differentiation. But any relationship is complex, and many details remain to be added to the picture sketched by the Greenberg, Guillemot and Kageyama laboratories [2] [3] [4] . Can Mash1 sequester the CBP/p300/Smad1 transcriptional coactivator or inhibit STAT activation just like Neurogenin1? Do other proneural bHLH proteins have similar activities? Does Notch promote gliogenesis by inhibiting proneural gene expression? Can Neurogenin2 or Mash1 play some positive role regulating glial differentiation or reinforcing commitment after glial lineage determination has occurred? This is a big step forward, but more work will be required before we really know how to make a commitment.
